BioSpace4h
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Hong Kong approves celebrity weight-loss drug, but experts say it’s not just to look good
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...
Eli Lilly and Company (LLY): Ken Fisher’s Bet on a Pharma Giant’s Growth Potential
We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
New Atlas18h
Weight-loss pill passes important safety test in clinical trial
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
The Motley Fool23h
Is Viking Therapeutics a Buy on the Dip?
Eli Lilly is studying two weight loss candidates in phase 3 trials ... A small player like Viking may also win by attracting ...